Please assess the completion status of the following clinical trial:

Trial Title: The Renin-Angiotensin-Aldosterone System and Parathyroid Hormone Control: The RAAS-PARC Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy subjects with with no medical problems (n=15) and individuals with primary hyperparathyroidism (n=30)~* normal blood pressure or stage 1 hypertension that is either untreated, or adequately treated with a single anti-hypertensive medication.~* Age \>18 years and \<80 years~* Estimated GFR \> 60ml/min~Exclusion Criteria:~* Chronic Kidney Disease or eGFR\<60~* Stage 2 or Stage 3 hypertension or the use of more than 1 antihypertensive drug~* Type 2 Diabetes Mellitus that is not controlled by diet or Metformin alone or with a Hemoglobin A1c \>7.5%~* History of liver failure~* History of heart failure~* The use of typical or atypical antipsychotic medications or lithium.~* Chronic inflammatory conditions (such as inflammatory bowel disease or arthritis) that are treated with prescribed doses of NSAIDs or glucocorticoids~* The use of prescribed doses of potassium supplements.~* Illness requiring overnight hospitalization in the past 6 months~* Active tobacco or recreational drug use~* Pregnancy or current breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- lisinopril (Type: EXPERIMENTAL): Lisinopril - open-label, 2.5-40mg daily

Based on this trial design, predict the completion outcome and termination type (if applicable).